@article{079cd32c18394b92abc9317761312cfc,
title = "Selection of biologics for patients with metastatic colorectal cancer: The role of predictive markers",
keywords = "EGFR, RAS, VEGF, aflibercept, bevacizumab, biologics, cetuximab, metastatic colorectal cancer, panitumumab, regorafenib",
author = "Kasi, {Pashtoon Murtaza} and Hubbard, {Joleen M.} and Axel Grothey",
note = "Funding Information: JM Hubbard has received research support from Genentech, Boston Biomedical Inc. and PRISM Pharma Co. A Grothey has received research support from Genentech, Bayer, Eisai, Pfizer and Eli-Lilly. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",
year = "2015",
month = mar,
day = "1",
doi = "10.1586/17474124.2015.1001743",
language = "English (US)",
volume = "9",
pages = "273--276",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "3",
}